妊娠期糖尿病治疗与子代早期儿童生长
该队列研究纳入816例妊娠期糖尿病(GDM)母婴,比较医学营养治疗(MNT)、格列本脲和胰岛素对子代至3岁生长的影响。尽管出生时格列本脲或胰岛素组子代体重、z评分和BMI高于MNT组,但6个月至3岁各治疗组子代生长无显著差异,提示GDM治疗对儿童早期生长无实质影响。
要点
- GDM治疗与子代出生时生长差异相关,但6个月至3岁生长无临床显著差异。
- 格列本脲治疗子代出生时生长指标高于MNT组,但随访至3岁无差异。
- 胰岛素治疗与3年内体重增加略多于MNT相关,但临床意义有限。
核心结论
- 尽管出生时存在生长差异,6个月至3岁各治疗组子代生长无有意义差异,包括格列本脲治疗者。
研究设计与样本
- 队列研究,纳入816例GDM孕妇及其2009-2012年分娩的子代,收集至3岁身高体重,采用线性混合模型分析。
主要发现
- 出生时格列本脲或胰岛素组子代体重、z评分和BMI高于MNT组。
- 6个月及1、2、3岁时所有子代体重、z评分和BMI相似。
- 控制协变量后,3年内体重z评分组间差异有统计学意义(P=0.01),但体重(P=0.06)或BMI变化(P=0.28)无差异。
- 配对比较显示胰岛素较MNT与更多体重增加相关(0.69 kg;95% CI,0.10-1.28;P=0.02)。
- 格列本脲较MNT体重z评分有降低趋势(-0.24;95% CI,-0.47至0.003;P=0.05)。
临床怎么用
- GDM治疗选择(MNT、格列本脲或胰岛素)对子代6个月至3岁生长无实质影响,支持现有治疗策略。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gestational diabetes mellitus (GDM) is associated with fetal overgrowth, and certain treatments are associated with an increased risk of macrosomia. However, there are limited data about the long-term effect of GDM treatment on childhood growth. METHODS: Cohort study of 816 women with GDM and their offspring delivered between 2009 and 2012. Childhood height and weight through age 3 were collected from the medical record and z-scores and body mass index (BMI) were calculated. We assessed the association between GDM treatment and childhood growth using linear mixed modeling. RESULTS: Treatment was divided into medical nutritional therapy (MNT) (n = 293), glyburide (n = 421), and insulin (n = 102). At delivery, birthweight, z-score, and BMI were higher in the offspring of women treated with either glyburide or insulin compared to MNT. However, weight, z-score, and BMI were similar among all offspring at 6 months and 1, 2, and 3 years of age. After controlling for covariates, there were differences in the weight z-score (P = 0.01) over the 3-year period by treatment group, but no differences in weight (P = 0.06) or change in BMI (P = 0.28). Pairwise comparisons indicated that insulin was associated with more weight gain compared with MNT (0.69 kg; 95% CI, 0.10-1.28; P = 0.02) and glyburide was associated with a trend toward lower weight z-score compared with MNT (-0.24; 95% CI, -0.47 to 0.003; P = 0.05). CONCLUSION: Despite growth differences detected at birth, we observed no meaningful differences in childhood growth from 6 months to 3 years among treatment groups, including in the offspring of women with GDM treated with glyburide.
引用
- Feghali M, Atlass J, Abebe KZ, et al. Treatment of Gestational Diabetes Mellitus and Offspring Early Childhood Growth. J Clin Endocrinol Metab. 2021. PMID: 33057663. doi:10.1210/clinem/dgaa742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。